The FDA Approved Remdesivir Based on a Trial in Which 3 out of 53 Children Died

Dr. Meryl Nass said, “Over 70% had an adverse reaction, 21% had a serious adverse event, and three of the children died. Because there was no control group, it’s unclear how either Gilead or the FDA determined that the drug benefited children, because there’s nothing to compare it to.”